A Phase 3 interventional study of Denosumab and Zoledronic Acid in Bone Metastases, sponsored by Amgen. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-11-07.
Sponsored by Amgen · Phase 3, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 43 studies in Multiple Myeloma by Amgen — none open to participants now, none under way, none of them phase 3. Multiple Myeloma · Amgen.
Among the 43 studies in Multiple Myeloma by Amgen, this one has the largest enrollment of the 40 interventional ones that give a count, is the only one that started in 2006, is one of 11 in phase 3, and was the 5th registered.
3,763 studies on the registry are indexed under Multiple Myeloma; 768 are open to participants now.
Browse Multiple Myeloma studies →None of the 43 studies in Multiple Myeloma by Amgen is open now. The open studies under Multiple Myeloma, anywhere →
Of the 584 Multiple Myeloma studies recruiting now, 429 (73%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
43 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 19 · Phase 2 16 · Phase 3 11 · Phase 4 1
First in 2005; this study’s year is marked. 1 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,779 is above the median of 41 across 3,008 interventional studies indexed under Multiple Myeloma.
Median enrollment 101 across the 40 interventional studies, 705 across the 1 observational. Of the 41 that completed or were terminated, 36 (88%) have results posted.
This tab as a report to print or save as PDF → With an account.
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 43 studies in Multiple Myeloma by Amgen, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine if denosumab is non-inferior to zoledronic acid (Zometa®) in the treatment of bone metastases (lytic bone lesions from multiple myeloma) in subjects with advanced cancer and multiple myeloma (excluding breast and prostate cancer)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
denosumab placebo with active zoledronic acid
Drug: Zoledronic Acid
active denosumab with zoledronic acid placebo
Biological: Denosumab
120 milligrams by subcutaneous injection every 4 weeks
4 milligrams intravenous Zoledronic Acid over minimum 15 minutes every 4 weeks
Also known as: Zometa
Time to the First On-Study Skeletal-Related Event (Non-Inferiority)
Time to the first on-study skeletal-related event (SRE) using a non-inferiority analysis. Median was estimated using the Kaplan-Meier method.
Time frame: up to 33 months
Time to First On-Study Skeletal-Related Event (Superiority)
Time to first on-study skeletal-related event (SRE) using a test for superiority. Median was estimated using the Kaplan-Meier method.
Time frame: up to 33 months
Time to the First-and-Subsequent On-Study Skeletal-Related Event
Time to the first-and-subsequent on-study skeletal-related event (SRE) using multiple event analysis. To be considered a subsequent SRE, the event must occur at least 21 days after the previous SRE. This outcome measure utilizes multiple event times, was analyzed based on a proportional mean model, and is therefore more appropriately summarized by the cumulative mean number of events.
Time frame: up to 33 months
Participants were enrolled from 21 June 2006 through 16 May 2008
| Milestone | Zoledronic Acid | Denosumab |
|---|---|---|
| Started | 890 | 886 |
| Received investigational product | 878 | 878 |
| Completed | 178 | 180 |
| Not completed | 712 | 706 |
| Withdrew: Death | 316 | 310 |
| Withdrew: Disease progression | 104 | 126 |
| Withdrew: Withdrawal by subject | 143 | 124 |
| Withdrew: Adverse event | 48 | 36 |
| Withdrew: Participant request | 31 | 22 |
| Withdrew: Lost to follow-up | 16 | 22 |
| Withdrew: Noncompliance | 15 | 17 |
| Withdrew: Physician decision | 1 | 2 |
| Withdrew: Protocol deviation | 0 | 2 |
| Withdrew: Ineligibility determined | 2 | 1 |
| Withdrew: Other | 36 | 44 |
Time to the first on-study skeletal-related event (SRE) using a non-inferiority analysis. Median was estimated using the Kaplan-Meier method.
| Days | Zoledronic Acid | Denosumab |
|---|---|---|
| Time to the First On-Study Skeletal-Related Event (Non-Inferiority) | 496.0 (371.00 to 589.00) | 625.0 (456.00 to NA) |
Time to first on-study skeletal-related event (SRE) using a test for superiority. Median was estimated using the Kaplan-Meier method.
| Days | Zoledronic Acid | Denosumab |
|---|---|---|
| Time to First On-Study Skeletal-Related Event (Superiority) | 496.0 (371.00 to 589.00) | 625.0 (456.00 to NA) |
Time to the first-and-subsequent on-study skeletal-related event (SRE) using multiple event analysis. To be considered a subsequent SRE, the event must occur at least 21 days after the previous SRE. This outcome measure utilizes multiple event times, was analyzed based on a proportional mean model, and is therefore more appropriately summarized by the cumulative mean number of events.
| Events | Zoledronic Acid | Denosumab |
|---|---|---|
| Time to the First-and-Subsequent On-Study Skeletal-Related Event | 436 | 392 |
Collected over up to 2 years 9 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Zoledronic Acid 4 mg Q4W | — | 581/878 (66.2%) | 767/878 (87.4%) |
| Denosumab 120 mg Q4W | — | 552/878 (62.9%) | 751/878 (85.5%) |
| Event | Zoledronic Acid 4 mg Q4W | Denosumab 120 mg Q4W |
|---|---|---|
| Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 100/878 | 103/878 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 54/878 | 55/878 |
| PneumoniaInfections and infestations | 44/878 | 52/878 |
| AnaemiaBlood and lymphatic system disorders | 49/878 | 25/878 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 40/878 | 45/878 |
| Metastases to central nervous systemNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 44/878 | 43/878 |
| General physical health deteriorationGeneral disorders | 38/878 | 26/878 |
| DehydrationMetabolism and nutrition disorders | 34/878 | 35/878 |
| Febrile neutropeniaBlood and lymphatic system disorders | 31/878 | 21/878 |
| Spinal cord compressionNervous system disorders | 26/878 | 27/878 |
| Event | Zoledronic Acid 4 mg Q4W | Denosumab 120 mg Q4W |
|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 264/878 | 234/878 |
| NauseaGastrointestinal disorders | 260/878 | 244/878 |
| FatigueGeneral disorders | 216/878 | 203/878 |
| ConstipationGastrointestinal disorders | 209/878 | 188/878 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 171/878 | 193/878 |
| AnorexiaMetabolism and nutrition disorders | 190/878 | 163/878 |
| Back painMusculoskeletal and connective tissue disorders | 183/878 | 169/878 |
| VomitingGastrointestinal disorders | 167/878 | 174/878 |
| CoughRespiratory, thoracic and mediastinal disorders | 151/878 | 172/878 |
| AstheniaGeneral disorders | 171/878 | 156/878 |
| Age, Continuous(Years) | Zoledronic Acid | Denosumab | Total |
|---|---|---|---|
| Mean | 60.6 ± 10.7 | 59.3 ± 11.4 | 59.9 ± 11.1 |
| Sex: Female, Male(Participants) | Zoledronic Acid | Denosumab | Total |
|---|---|---|---|
| Female | 338 | 298 | 636 |
| Male | 552 | 588 | 1140 |
| Race/Ethnicity, Customized(Participants) | Zoledronic Acid | Denosumab | Total |
|---|---|---|---|
| White or Caucasian | 770 | 770 | 1540 |
| Black or African American | 29 | 20 | 49 |
| Hispanic or Latino | 36 | 49 | 85 |
| Asian | 44 | 36 | 80 |
| Japanese | 1 | 3 | 4 |
| American Indian or Alaska Native | 2 | 0 | 2 |
| Other | 8 | 8 | 16 |
| Tumor Type Stratification Factor(Participants) | Zoledronic Acid | Denosumab | Total |
|---|---|---|---|
| Multiple myeloma | 93 | 86 | 179 |
| Other | 452 | 457 | 909 |
| Non-small cell lung cancer | 345 | 343 | 688 |
| Previous Skeletal-Related Event Stratification Factor(Participants) | Zoledronic Acid | Denosumab | Total |
|---|---|---|---|
| Yes | 446 | 440 | 886 |
| No | 444 | 446 | 890 |
| Systematic Anti-Cancer Therapy Stratification Factor(Participants) | Zoledronic Acid | Denosumab | Total |
|---|---|---|---|
| Yes | 747 | 746 | 1493 |
| No | 143 | 140 | 283 |
No study locations are listed for this record.
Ran from Jun 2006 to primary completion in Apr 2009, 34 months.
Results were first posted in Apr 2014, 5 years after primary completion. A results delay was requested in Jun 2010.
Of 108 industry-sponsored phase 3 interventional studies under Multiple Myeloma, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 66. This study's 34 months is below that.
Counting every sponsor, half of 180 studies reached it within 55 months; a quarter within 34 and three quarters within 95.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Denosumab